Chronic Renal Failure, Hemodialysis
Conditions
Keywords
Clopidogrel Resistance, prasugrel, Hemodialysis
Brief summary
Clopidogrel administration is essential in patients undergoing percutaneous coronary intervention, in patients with previous stroke, in patients under chronic hemodialysis via fistulae and in patients with chronic atrial fibrillation if coumarin administration is not a viable option. Patients with chronic renal failure present lower clopidogrel response compared to those with normal renal function. Additionally, hemodialysis via the dialysis filter causes a decrease in glycoprotein platelet receptors, potentially associated with thienopyridine hyporesponsiveness. Clopidogrel resistant patients as assessed by VerifyNow P2Y12(Accumetrics)will be randomized in 1:1 fashion to prasugrel 10mg/day or clopidogrel 150mg/day. On day 15±2 days a crossover directly to the alternate treatment group will be carried out, without an interventing washout period. All patients will undergo platelet reactivity assessment, documentation of major adverse cardiac events and documentation of any serious adverse events(stroke, bleeding)at day 15 and day 30.
Interventions
DRUGPrasugrel
Prasugrel 10 mg/day for 15 days
DRUGClopidogrel
Clopidogrel 150 mg/day for 15 days
Sponsors
University of Patras
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years old 2. History of chronic renal failure under hemodialysis for at least 6 months 3. Under clopidogrel 75mg/day treatment for at least 7 days before randomization 4. Informed consent obtained in writing
Exclusion criteria
1. Treatment with other investigational agents (including placebo) or devices within 30 days prior to randomization or planned use of investigational agents or devices prior to the Day 30 visit. 2. Pregnancy 3. Breastfeeding 4. Inability to give informed consent or high likelihood of being unavailable for the Day 30 follow up. 5. Malignancy 6. Acute coronary syndrome or hemodynamic instability within 30 days prior to randomization 7. Requirement for oral anticoagulant prior to the Day 30 visit 8. Requirement for discontinuation of thienopyridine treatment prior to the Day 30 visit 9. Treatment with IIb/IIIa inhibitors within 30 days prior to randomization or planned administration prior to the Day 30 visit 10. Known hypersensitivity to prasugrel or clopidogrel. 11. History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 6 months. 12. Other bleeding diathesis, or considered by investigator to be at high risk for bleeding on thienopyridine therapy. 13. Any previous history of ischemic stroke, intracranial hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm). 14. Thrombocytopenia (\<100.000 / μL) at randomization 15. Known liver failure (bilirubin \> 2mg/dl)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet Reactivity Units (PRU)assessed by VerifyNow P2Y12(Accumetrics) | Day 30 |
Secondary
| Measure | Time frame |
|---|---|
| Major Adverse Cardiac Events (death, myocardial infarction, revascularization) | Day 30 |
| Hemorrhage | Day 30 |
| Stroke | Day 30 |
Countries
Greece
Outcome results
None listed